Madrigal Pharmaceuticals, Inc. (MDGL)

Nasdaq · Healthcare · Biotechnology
$379.10-4.45%As of 2026-11-22 · USD
Last session low $377.91Last session high $399.43
52-week low $353.5452-week high $615.00
Market cap
$8.81B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)28.1In the oversold range (below 30)
MACD (12, 26, 9)-16.22Below its signal line (-15.77); histogram -0.45
Bollinger %B (20, 2)-9%Below the lower band (385.24 to 452.51)
SMA 20418.88Price is 9.5% below
SMA 50462.49Price is 18.0% below
SMA 200494.12Price is 23.3% below
ATR (20)5.38% of priceAverage true range per day
52-week position10%In the lower part of the 353.54 to 615.00 range

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Insider filings, 90 daysNo purchases and 2 sales (about $6.2M).
Latest fiscal yearEnded 2025-12-31: revenue of $958.40M and an operating margin of -31.3%.

More in Biotechnology